← Library
A cosmetic ingredient, not regulated or approved as a drug. This page is educational information only, not medical advice.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Dipeptide diaminobutyroyl benzylamide diacetate

Cosmetic ingredient

Cosmetic synthetic peptide

Also known as: Syn-Ake, snake peptide, Syn-ake, Syn-Ake acetate, SYN-AKE Diacetate, Serpent Peptide 2AcOH, SYN-AK, orb1299405, betaAla-Pro-Dab-NHBn.2CH3CO2H

Evidence score
23/ 100
Thin evidence

Very thin human evidence

  • Regulatory standing. Cosmetic ingredient, not regulated as a drug
  • Animal / preclinical only. Evidence is largely animal or in-vitro
  • No registered human trials. Nothing registered on ClinicalTrials.gov
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Dipeptide diaminobutyroyl benzylamide diacetate, sold as Syn-Ake, is a small synthetic peptide used in topical skincare products. It was designed to mimic the activity of a component of temple viper venom and is thought to act as an antagonist at the muscle nicotinic acetylcholine receptor, which the manufacturer suggests may reduce facial muscle contraction and the appearance of expression lines.

What the evidence shows

Automatic summaryAnimal / preclinical

It is marketed as a cosmetic ingredient, not an FDA-approved drug, and there are no registered human clinical trials. Evidence is limited to a small number of publications and manufacturer-reported data, so claims about wrinkle reduction are not well established by independent research.

Key facts

Molecular formula
C23H37N5O7
Molecular weight
495.6 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies
Nonemost advanced phase
0completed (sample)
0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

2papers referencing Dipeptide diaminobutyroyl benzylamide diacetate

The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies.

Int J Cosmet Sci2026

COMPOSITION FOR TREATMENT OF HYPERHIDROSIS

2011

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.